What is Valencia Technologies?
Valencia Technologies Corporation operates at the intersection of bioelectronic medicine and minimally invasive surgery. The company is primarily recognized for the development of the eCoin Peripheral Neurostimulator, a compact, nickel-sized device designed to address chronic conditions such as overactive bladder. Unlike traditional, more invasive surgical interventions, the eCoin system is engineered for rapid deployment, requiring only a 20-minute office-based procedure under local anesthesia. This technological differentiation positions Valencia Technologies as a disruptive force in the neuromodulation sector, offering a patient-centric alternative that reduces the clinical burden and recovery time associated with conventional implantable pulse generators. The company is currently navigating the rigorous requirements of a pivotal trial to support pre-market approval, underscoring its commitment to evidence-based medical innovation.
How much funding has Valencia Technologies raised?
Valencia Technologies has raised a total of $35.1M across 2 funding rounds:
Debt
$150K
Other Financing Round
$35M
Debt (2020): $150K with participation from PPP
Other Financing Round (2025): $35M led by Brooks Advisory Group
Key Investors in Valencia Technologies
Brooks Advisory Group
Brooks Advisory Group is an investment banking firm based in Apex, North Carolina, providing strategic financial advisory services to growing enterprises.
PPP
Public-Private Partnership
What's next for Valencia Technologies?
With the recent influx of capital, Valencia Technologies is expected to prioritize the completion of its pivotal clinical trial and the subsequent submission of its pre-market approval application. The strategic focus will likely shift toward scaling operational capabilities and refining the commercialization roadmap for the eCoin platform. As the company transitions from a development-stage entity to a commercial-ready enterprise, stakeholders will be monitoring the regulatory progress and the potential for broader therapeutic applications of its neurostimulation technology. This major strategic investment provides the necessary runway to solidify the company's market position and address the unmet needs of patients suffering from urological disorders, potentially setting a new standard for peripheral nerve stimulation in outpatient settings.
See full Valencia Technologies company page
